{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=8&q=castration-resistant", "query": { "q": "castration-resistant", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 768, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=9&q=castration-resistant&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=7&q=castration-resistant&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T11:44:25.690Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02097303", "title": "Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Carolina Research Professionals, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 36, "start_date": "2014-03", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2018-02-01", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 5, "location_summary": "Towson, Maryland • Omaha, Nebraska • Syracuse, New York + 2 more", "locations": [ { "city": "Towson", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" }, { "city": "Springfield", "state": "Oregon" }, { "city": "Myrtle Beach", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02097303" }, { "nct_id": "NCT03787680", "title": "Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "AZD6738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 49, "start_date": "2019-10-31", "completion_date": "2028-08", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • Charlottesville, Virginia", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03787680" }, { "nct_id": "NCT06120491", "title": "Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1898, "start_date": "2023-11-21", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-11-10", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 71, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 63 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06120491" }, { "nct_id": "NCT07723248", "title": "A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration Resistant Prostate Cancer" ], "interventions": [ { "name": "Rinzimetostat", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORIC Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 600, "start_date": "2026-08-03", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 14, "location_summary": "Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Jeffersonville", "state": "Indiana" }, { "city": "Holland", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07723248" }, { "nct_id": "NCT00544440", "title": "An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Neoplasms" ], "interventions": [ { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 57, "start_date": "2007-10", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-07-17", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00544440" }, { "nct_id": "NCT02677376", "title": "Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "18F-Sodium Fluoride (NaF)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 7, "start_date": "2016-06-27", "completion_date": "2020-01-03", "has_results": false, "last_update_posted_date": "2020-02-26", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02677376" }, { "nct_id": "NCT04122976", "title": "A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Darolutamide(Nubeqa, BAY1841788)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 805, "start_date": "2020-01-30", "completion_date": "2026-10-07", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 24, "location_summary": "Homewood, Alabama • Tucson, Arizona • San Diego, California + 21 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Englewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04122976" }, { "nct_id": "NCT03218826", "title": "PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Prostate Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Castration-Resistant Prostate Carcinoma", "Metastatic Breast Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Prostate Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage III Prostate Cancer AJCC v8", "Stage IIIA Prostate Cancer AJCC v8", "Stage IIIB Prostate Cancer AJCC v8", "Stage IIIC Prostate Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "PI3Kbeta Inhibitor AZD8186", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-09-24", "completion_date": "2025-10-13", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 8, "location_summary": "Aurora, Colorado • Baltimore, Maryland • Bethesda, Maryland + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Middletown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03218826" }, { "nct_id": "NCT06216249", "title": "Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Carcinoma", "Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Gallium Ga 68 Gozetotide", "type": "OTHER" }, { "name": "Lutetium Lu 177 Vipivotide Tetraxetan", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 90, "start_date": "2024-08-01", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06216249" }, { "nct_id": "NCT03674814", "title": "Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Relacorilant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 42, "start_date": "2018-10-23", "completion_date": "2024-06-10", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-11-15T11:44:25.690Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03674814" } ] }